Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma.
David F McDermottJae Lyun LeeGeorg Arnold BjarnasonJames M G LarkinRustem Airatovich GafanovMark D KochenderferNiels Viggo JensenFrede DonskovJahangeer MalikAlexandr PoprachScott S TykodiTeresa Alonso-GordoaDaniel C ChoPoul F GeertsenMiguel Angel Climent DuranChristopher DiSimoneRachel Kloss SilvermanRodolfo F PeriniCharles SchlossMichael B AtkinsPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Single-agent pembrolizumab showed promising antitumor activity as a first-line treatment in patients with advanced ccRCC, with durable responses across International Metastatic RCC Database Consortium categories. Safety and tolerability profile of pembrolizumab monotherapy was comparable to what has been previously described in other tumor types.
Keyphrases